AGMBAgomAb Therapeutics NV
Is it safe?
Mostly sound, with a caveat: insiders buying, but big price swings.
Multiple insiders bought with their own money (net +$267K, 90 days to Oct 8, 2026).
Large price swings, high volatility. Worst drawdown -51% · now 48% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AGMB take a bad year?
The deepest fall in AGMB's price history on file is −51%; it is 48% below its high today.
Worst drawdown on file · −48% today
- Annualised volatility
- 93%
Annualised volatility · three times the market's own swing
Details›
- Annualised volatilitytwo years of daily moves
- 93%
- Worst drawdown on file
- −51%
- Below its 52-week high
- 48%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry